Every year over 500,000 people die from viral respiratory infections and over $200 billion is lost due to losses in productivity. Whilst treatments and vaccines exist, they can only only be used for specific viruses and viral strains. Treatments are especially limited, due to either only being able to target specific viruses (requiring identification) or having limited broad spectrum efficacy. RespImmune are using their world leading expertise in defective interfering particles to create the world's first truly broad-spectrum respiratory antiviral.